The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

XIE Yangfan ¹ , CAO Lingmin ² , WANG Xueyuan ¹ , LIN Chuan ³ ,  HUANG Hairong ¹

1. Department of Epidemiology, School of Public Health, Hainan Medical University, Haikou 571199, P. R. China;
2. Guangyuan Lizhou District Center for Disease Control and Prevention, Guangyuan 628000, P. R. China;
3. The Library of Hainan Medical College, Haikou 571199, P. R. China;

Corresponding?author：

HUANG Hairong, Email: 474938175@qq.com

Keywords：

Pancreatic cancer; Gut microbiota; Diversity composition; Systematic review; Meta-analysis; Cross-sectional study

DOI：

10.7507/1672-2531.202208011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the intestinal flora diversity profile of pancreatic cancer patients. Methods The Cochrane Library, PubMed, Web of Science, EMbase, CNKI, CBM, WanFang Data and VIP databases were electronically searched to collect cross-sectional studies on the intestinal flora diversity profile of pancreatic cancer patients from inception to December 31, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies; then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 7 cross-sectional studies involving 250 pancreatic cancer patients and 166 healthy controls were included. The results of meta-analysis showed that: compared with the healthy control group, the intestinal flora of patients with pancreatic cancer α reduced diversity with the Shannon index. High-throughput sequencing found that Proteobacteria and Prevotella were more abundant in pancreatic cancer patients, Firmicutes, Faecalbacterium, Bifidobacterium and Clostridium in pancreatic cancer patients was lower. Conclusion Current evidence shows that the intestinal flora of pancreatic cancer patients has certain characteristics. Proteobacteria and Prevotella are relatively abundant in pancreatic cancer patients. Due to limited quality and quantity of the included studies, more high-quality studies are needed to verify above conclusion.

Citation： XIE Yangfan, CAO Lingmin, WANG Xueyuan, LIN Chuan, HUANG Hairong. The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(2): 186-190. doi: 10.7507/1672-2531.202208011 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
3.	Sun ZX, Shen YM, Sun ZK, et al. Survival analysis of 198 patients with pancreatic cancer in Hainan, China: A multi-institution prospective study. Asian Pac J Trop Med, 2019, 12(14): 1-13.
4.	朱鑫哲, 李浩, 徐華祥, 等. 2021年胰腺癌研究及診療新進展. 中國癌癥雜志, 2022, 32(1): 1-12.
5.	趙思涵, 鄭健. 胰腺癌病因及發病機制研究進展. 中國癌癥防治雜志, 2022, 14(3): 253-263.
6.	中華醫學會外科學分會胰腺外科學組. 中國胰腺癌診治指南(2021). 中華外科雜志, 2021, 59(7): 561-577.
7.	吳白駿, 胡朝全. 胰腺癌免疫治療的現狀與進展. 實用臨床醫藥雜志, 2022, 26(13): 134-138, 144.
8.	侯志穎. 胰腺癌危險因素及其腸道菌群多樣性研究. 海口: 海南醫學院, 2020.
9.	陳恬. 基于微生物組學的胰腺癌患者口腔及腸道菌群研究. 上海: 海軍軍醫大學, 2020.
10.	Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 2012, 9(10): 577-589.
11.	田智敏. 參苓白術散對胰腺癌營養狀況的改善及胰腺癌與腸道菌群和免疫的關系研究. 上海: 上海中醫藥大學, 2019.
12.	鄧寒丹, 范興麗. 腸道菌群在腫瘤發生發展及免疫治療中作用的研究進展. 生物工程學報, 2022, 38(6): 2105-2119.
13.	涂希晨. 胰腺癌患者腸道微環境的研究. 長沙: 湖南師范大學, 2020.
14.	Ren Z, Jiang J, Xie H, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 2017, 8(56): 95176-95191.
15.	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov, 2018, 8(4): 403-416.
16.	曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四: 觀察性研究的質量評價工具. 中國循證心血管醫學雜志, 2012, 4(4): 297-299.
17.	陳卓, 錢祥, 張愛琴, 等. 基于腸道菌群結構特征研究胰腺癌不同中醫證型與預后的相關性. 浙江中西醫結合雜志, 2019, 29(12): 965-969.
18.	張德, 周文麗, 王雷, 等. 女性胰腺癌患者腸道菌群變化分析. 解放軍醫學院學報, 2019, 40(11): 1087-1092, 1109.
19.	謝國群, 張院輝, 郭曉冬, 等. 基于高通量測序技術的胰腺癌濕熱證患者腸道菌群結構差異與功能變異研究. 上海中醫藥雜志, 2019, 53(12): 9-16.
20.	Zhou W, Zhang D, Li Z, et al. The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing. J Transl Med, 2021, 19(1): 215.
21.	Wang X, Sun Z, Makale EC, et al. Gut microbial profile in patients with pancreatic cancer. Jundishapur J Microbiol, 2022, 15(4): e122386.
22.	Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut, 2022, 71(7): 1359-1372.
23.	Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut, 2021, 70(8): 1419-1425.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
3. Sun ZX, Shen YM, Sun ZK, et al. Survival analysis of 198 patients with pancreatic cancer in Hainan, China: A multi-institution prospective study. Asian Pac J Trop Med, 2019, 12(14): 1-13.
4. 朱鑫哲, 李浩, 徐華祥, 等. 2021年胰腺癌研究及診療新進展. 中國癌癥雜志, 2022, 32(1): 1-12.
5. 趙思涵, 鄭健. 胰腺癌病因及發病機制研究進展. 中國癌癥防治雜志, 2022, 14(3): 253-263.
6. 中華醫學會外科學分會胰腺外科學組. 中國胰腺癌診治指南(2021). 中華外科雜志, 2021, 59(7): 561-577.
7. 吳白駿, 胡朝全. 胰腺癌免疫治療的現狀與進展. 實用臨床醫藥雜志, 2022, 26(13): 134-138, 144.
8. 侯志穎. 胰腺癌危險因素及其腸道菌群多樣性研究. 海口: 海南醫學院, 2020.
9. 陳恬. 基于微生物組學的胰腺癌患者口腔及腸道菌群研究. 上海: 海軍軍醫大學, 2020.
10. Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol, 2012, 9(10): 577-589.
11. 田智敏. 參苓白術散對胰腺癌營養狀況的改善及胰腺癌與腸道菌群和免疫的關系研究. 上海: 上海中醫藥大學, 2019.
12. 鄧寒丹, 范興麗. 腸道菌群在腫瘤發生發展及免疫治療中作用的研究進展. 生物工程學報, 2022, 38(6): 2105-2119.
13. 涂希晨. 胰腺癌患者腸道微環境的研究. 長沙: 湖南師范大學, 2020.
14. Ren Z, Jiang J, Xie H, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 2017, 8(56): 95176-95191.
15. Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov, 2018, 8(4): 403-416.
16. 曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四: 觀察性研究的質量評價工具. 中國循證心血管醫學雜志, 2012, 4(4): 297-299.
17. 陳卓, 錢祥, 張愛琴, 等. 基于腸道菌群結構特征研究胰腺癌不同中醫證型與預后的相關性. 浙江中西醫結合雜志, 2019, 29(12): 965-969.
18. 張德, 周文麗, 王雷, 等. 女性胰腺癌患者腸道菌群變化分析. 解放軍醫學院學報, 2019, 40(11): 1087-1092, 1109.
19. 謝國群, 張院輝, 郭曉冬, 等. 基于高通量測序技術的胰腺癌濕熱證患者腸道菌群結構差異與功能變異研究. 上海中醫藥雜志, 2019, 53(12): 9-16.
20. Zhou W, Zhang D, Li Z, et al. The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing. J Transl Med, 2021, 19(1): 215.
21. Wang X, Sun Z, Makale EC, et al. Gut microbial profile in patients with pancreatic cancer. Jundishapur J Microbiol, 2022, 15(4): e122386.
22. Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut, 2022, 71(7): 1359-1372.
23. Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut, 2021, 70(8): 1419-1425.

Previous Article
Screening accuracy for four common questionnaires of chronic obstructive pulmonary disease: a network meta-analysis
Next Article
The adverse reactions of piperacillin: a systematic review

Chinese Journal of Evidence-Based Medicine

The composition spectrum of intestinal bacterial diversity in Chinese pancreatic cancer patients: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content